Tested Applications
Positive WB detected in | HEK-293 cells |
Positive IF/ICC detected in | HEK-293 cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:1000-1:6000 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
86330-1-RR targets Phospho-ATR (Ser428) in WB, IF/ICC, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Recombinant |
Type | Antibody |
Immunogen |
fusion protein Predict reactive species |
Full Name | ataxia telangiectasia and Rad3 related |
Calculated Molecular Weight | 301 kDa |
Observed Molecular Weight | 300 kDa |
GenBank Accession Number | NM_001184 |
Gene Symbol | ATR |
Gene ID (NCBI) | 545 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
UNIPROT ID | Q13535 |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Ataxia-telangiectasia and Rad3 related (ATR) is a serine/threonine kinase and a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, particularly the ataxia telangiectasia mutated (ATM) subfamily. The phosphorylation site of ATR is located at Ser428 and is crucial for proper ATR function. In a series of breast cancer studies, high ATR expression and activation were significantly associated with higher tumor stage, mitotic index, pleomorphism, lymphovascular invasion, and poor survival. (PMID: 33854565)
Protocols
Product Specific Protocols | |
---|---|
WB protocol for Phospho-ATR (Ser428) antibody 86330-1-RR | Download protocol |
IF protocol for Phospho-ATR (Ser428) antibody 86330-1-RR | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |